IONS vs LNTH
Ionis Pharmaceuticals, Inc. vs Lantheus Holdings — AI-powered side-by-side comparison
IONS
Ionis Pharmaceuticals, Inc.
43
Reduce
VS
LNTH
Lantheus Holdings
67
Buy
| Metric | IONS | LNTH |
|---|
| AI Score |
43
|
67
|
| Price |
$55.38
|
$100.63
|
| P/E Ratio |
-16.02×
|
23.91×
|
| ROE |
-77.9%
|
21.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
98.2%
|
60.1%
|
| Debt / Equity |
5.50×
|
0.44×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
46.6
|
42.5
|
| Beta |
0.4
|
-0.057
|
| Expected Upside |
—
|
+7.8%
|
AI Committee View
Current Innellis committee reasoning for IONS versus LNTH.
LNTH leads by 24 points.
LNTH scores 67/100 (Buy) versus IONS at 43/100 (Reduce).
IONS Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -7.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 26.2x prices in significant intangible value — Value
- ROE of only -110.9% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 4.77 adds balance-sheet risk to the value case — Value
LNTH Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical